OBJECTIVE: To investigate the usefulness of apparent diffusion coefficient (ADC) values in predicting true Gleason scores from radical prostatectomy specimen (tGS), compared with systematic transrectal ultrasound (TRUS)-guided biopsy GS (bGS).
MATERIALS AND METHODS: One hundred and five patients with biopsy-proven prostate cancer underwent preoperative DWI (b-values of 0, 1000, and 2000s/mm2) of 3-T MRI. The mean and minimum ADCs of visible tumors were calculated for either of a pair of b-values: 0 and 1000s/mm2 (ADC1000, or 0 and 2000s/mm2 (ADC2000), and relationships between the four ADC parameters and tGS evaluated for the peripheral zone (PZ) and transition zone (TZ). For multiple tumors, the dominant tumor's GS and ADCs were estimated for cancer aggressiveness assessment by computing ROC curves.
RESULTS: Significant negative correlations were observed between tGS and mean ADC1000, mean ADC2000, minimum ADC1000, and minimum ADC2000 (r=-0.41, -0.39, -0.39, and -0.37, respectively) of 100 visible PZ tumors and 66 visible TZ tumors (r=-0.40, -0.42, -0.29, and -0.21, respectively). For distinguishing high-grade from low/intermediate-grade PZ lesions, the areas under the curve (AUCs) of mean ADC1000 (0.751), mean ADC2000 (0.710), minimum ADC1000 (0.768), and minimum ADC2000 (0.752) were similar to that of the highest bGS (0.708) (p=0.61, p=0.98, p=0.47, and p=0.60, respectively). For distinguishing high-grade from low/intermediate-grade TZ lesions, AUCs of mean ADC1000 (0.779), and mean ADC2000 (0.811) were similar to that of the highest bGS (0.805) (p=0.83 and p=0.97).
CONCLUSION: Tumor ADCs obtained with high b-values could predict prostate cancer aggressiveness as effectively as systematic TRUS-guided biopsy.
Written by:
Kitajima K, Takahashi S, Ueno Y, Miyake H, Fujisawa M, Kawakami F, Sugimura K. Are you the author?
Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan.
Reference: Eur J Radiol. 2013 Mar 18. pii: S0720-048X(13)00107-1.
doi: 10.1016/j.ejrad.2013.02.021
PubMed Abstract
PMID: 23518144
UroToday.com Prostate Cancer Section
